Streamlining Sight: Bausch + Lomb's New Tool in Cataract Surgery

VAUGHAN, ONTARIO – July 16, 2026 – In a world where over 30 million cataract surgeries are performed annually, the quest for marginal gains in the operating room—gains measured in seconds of time and millimeters of precision—is relentless. Bausch + Lomb, a nearly two-century-old stalwart in eye health, has just made its latest move in this high-stakes arena with the U.S. launch of its EyeGility™ Inserter, a preloaded delivery system for intraocular lenses (IOLs).

Cataract surgery involves replacing the eye's clouded natural lens with a clear, artificial IOL. For decades, this involved a delicate, multi-step process where a technician or surgeon would manually fold and load the IOL into an injector. The EyeGility system aims to simplify this critical moment by providing the lens preloaded in a sterile, single-use device, designed for one-handed operation.

“The enVista IOL platform has long been appreciated by surgeons for its glistening-free optic and differentiated optic portfolio to suit a wide range of patients,” said Wayne Caulder, vice president and general manager for North America Surgical at Bausch + Lomb. “The launch of EyeGility enables surgeons to continue delivering these benefits to their patients while also gaining the efficiencies and advantages offered by this preloaded IOL delivery system.”

The Systemic Push for Surgical Efficiency

The introduction of EyeGility is not happening in a vacuum. It taps directly into the immense pressures facing modern healthcare systems. The global cataract surgery device market, valued at over $9 billion in 2024, is projected to swell to nearly $16 billion by 2035, propelled by an aging global population. This growth demands not just more procedures, but more efficient and safer ones.

Preloaded IOL systems are a direct answer to this demand. Studies have shown they can shave nearly 30 seconds off each procedure. While that may seem insignificant, across millions of surgeries, it translates into thousands of hours of reclaimed operating room time. More importantly, these systems are engineered to reduce risk. By eliminating manual handling of the IOL, they minimize the chance of lens damage or, more critically, contamination that can lead to postoperative complications.

This focus on sterility has become paramount. Complications like Toxic Anterior Segment Syndrome (TASS), a sterile inflammation that can cause temporary vision loss after surgery, are a constant concern for ophthalmologists. The entire industry is vigilant, and Bausch + Lomb itself initiated a voluntary recall for specific lots of its enVista lenses in early 2025 after observing an increased frequency of TASS reports. The company's investigation concluded the issue was not a flaw in the lens design itself, and the new EyeGility system, with its sealed, untouched IOL, represents a step forward in mitigating such environmental risks. The device’s FDA 510(k) clearance in late 2024 and the more stringent Premarket Approval (PMA) for co-packaging the lens and inserter, granted in June 2026, signal regulatory confidence in the manufacturing and packaging process.

A Crowded Field of Precision Instruments

Bausch + Lomb enters a competitive landscape where rivals have already established their own advanced delivery systems. Alcon, a major competitor, offers both the UltraSert™ system, known for its controlled plunger, and the AutonoMe, which uses a CO2-powered mechanism for automated, single-handed delivery. Johnson & Johnson Vision has its Tecnis Simplicity system, a fully disposable preloaded injector praised by surgeons for its reliability. Hoya Surgical Optics was a pioneer in this space, receiving FDA approval for its iSert® preloaded system back in 2009.

Against this backdrop, EyeGility's design details are its key differentiators. The system is designed for a 2.4mm incision, aligning with the industry-wide trend of minimally invasive surgery that promotes faster healing. Its balanced, manual push force is intended to give surgeons a tactile, predictable feel during lens delivery. One of its most practical features, however, may be its 20-minute standby time—the window from initial preparation to the moment of injection. In the unpredictable environment of an operating room, where delays can occur, this extended timeframe provides a valuable buffer of flexibility for the surgical team.

“Any system that reduces variables and simplifies workflow is a win,” commented one ophthalmic surgeon not involved with the product’s launch. “A preloaded device takes one potential point of failure—manual loading—off the table. That enhances safety, consistency, and lets me focus entirely on the patient.”

The View from the Surgeon's Microscope

Ultimately, the success of any surgical device is determined in the hands of the person using it. Bausch + Lomb is banking on a combination of familiarity and improved ergonomics. The EyeGility is paired with the company’s established enVista IOLs—both the Aspire model, which slightly extends depth of focus, and the Envy trifocal lenses, designed to reduce the need for reading glasses.

Dr. Parag Parekh, a surgeon from Pennsylvania quoted in the company’s announcement, affirmed the system’s performance. “I frequently choose enVista IOLs for my patients, and in my hands, the EyeGility inserter has consistently provided a smooth, comfortable IOL delivery,” he stated.

The emphasis on “smooth” and “comfortable” delivery is more than marketing jargon. An uncontrolled, rapid injection of the IOL can damage the delicate capsular bag that holds the lens in place. The EyeGility's silicone soft-tipped plunger and balanced mechanics are engineered to prevent this, ensuring the folded lens unfurls gently and predictably within the eye. By pairing this refined delivery mechanism with its premium IOL technology, Bausch + Lomb is making a strategic play to not only defend but expand its footprint in the highly competitive and technologically advanced world of sight restoration.